ENLV

Enlivex Therapeutics Ltd. · NASDAQ

Sector Health Technology
Industry Biotechnology
Website enlivex.com
Employees(FY) -
ISIN IL0011319527

Performance

-7.19%

1W

-61.25%

1M

-41.73%

3M

-20.51%

6M

-42.59%

YTD

-48.16%

1Y

Profile

Enlivex Therapeutics Ltd. operates as a clinical-stage macrophage reprogramming immunotherapy company. It is developing Allocetra, a cell-based therapy to treat organ dysfunction and failure associated with sepsis that is in phase II clinical trial, as well as in preclinical trial to treat solid tumors. The company has a collaboration agreement with BeiGene to evaluate the safety and efficacy of Allocetra in combination with tislelizumab, an anti-PD-1 immune checkpoint inhibitor for the treatment of patients with advanced-stage solid tumors. Enlivex Therapeutics Ltd. is headquartered in Ness Ziona, Israel.

Advanced Technical Analysis

Technical Analysis of ENLV 2024-05-03

Overview:

In analyzing the technical indicators for ENLV over the last 5 days, we will delve into the trend, momentum, volatility, and volume indicators to provide a comprehensive outlook on the possible stock price movement in the coming days.

Trend Analysis:

Moving Averages (MA): The 5-day Moving Average (MA) has been showing an upward trend,...

See more ...

Recent News & Updates

2024-04-28 20:00
Enlivex CEO Issues Letter to Shareholders Perspectives on Recent Events(Globenewswire)
2024-04-21 20:00
Enlivex Announces Dosing of First Two Patients in its Randomized, Controlled Phase I/II Trial Evaluating Allocetra in Patients with Knee Osteoarthritis(Globenewswire)
2024-04-15 19:50
Enlivex Announces Authorization from the Danish Regulatory Agency for the Company's Randomized, Controlled Phase I/II Trial Evaluating Allocetra in Patients with Knee Osteoarthritis(Globenewswire)
2024-04-15 01:01
Enlivex (ENLV) Stock Plummets 51% in a Week: Here's Why(Zacks)
2024-04-11 02:58
Enlivex to Host Webcast on April 12, 2024 at 8:30 a.m. Eastern Time to Discuss Topline Results from Its Phase II Trial Evaluating Allocetra In Patients with Sepsis(Globenewswire)
2024-04-10 20:05
Enlivex Announces Topline Results of Its Phase II Trial Evaluating Allocetra In Patients With Sepsis(Globenewswire)
2024-04-04 19:52
ENLV Stock Earnings: Enlivex Therapeutics Misses EPS for Q4 2023(Investorplace)
2024-03-21 22:50
Enlivex Therapeutics and Unusual Machines Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV(Accesswire)
2024-02-25 19:30
Enlivex Receives Regulatory Authorization From Israel's Health Ministry For The Initiation Of Phase 1/2 Trial Evaluating Allocetra In Patients With Knee Osteoarthritis(Accesswire)
2024-02-20 19:30
Enlivex Completes Enrollment Of All 120 Patients In Phase 2 Trial Of Allocetra In Patients With Sepsis, Third-Leading Cause Of Mortality In US Hospitals(Accesswire)
2024-02-06 19:00
Enlivex Announces Issuance of New U.S. Patent Covering Allocetra Cells and Their Manufacturing Method(Globenewswire)
2024-01-16 19:00
Enlivex Receives IMOH Regulatory Authorization for the Initiation of a Multi-Country, Randomized, Controlled Phase I/II Trial Evaluating Allocetra in Up To 160 Patients with Moderate to Severe Knee Osteoarthritis(Globenewswire)
2023-12-19 19:00
Enlivex Announces Completion of Enrollment of Its Phase II Trial Evaluating Allocetra In Patients With Sepsis(Globenewswire)
2023-11-20 18:00
MediWound Announces Appointment of Shmulik Hess, Ph.D. as Chief Operating Officer and Chief Commercial Officer(Globenewswire)
2023-09-10 20:00
Enlivex Announces Reprioritization Plan and Second Quarter 2023 Financial Results(Yahoo Finance)
2023-09-06 20:00
Enlivex to Present at the H.C. Wainwright 25th Annual Global Investment Conference(Yahoo Finance)
2023-08-01 20:00
Enlivex Announces Peer-Reviewed Publication in Frontiers in Immunology of Clinical Data Details Resolution of Acute Respiratory Distress Syndrome (ARDS) from two Phase I/II Trials Evaluating Allocetra in Patients with COVID-19(Yahoo Finance)
2023-07-30 20:00
Enlivex Announces Dosing of First Patient Under The Amended Protocol Of Its Phase II trial Evaluating Allocetra In Patients With Sepsis(Yahoo Finance)
2023-06-25 20:00
Enlivex Announces First Quarter 2023 Financial Results and Provides a Business Update(Yahoo Finance)
2023-06-05 20:00
Enlivex to Present at the 2023 Jefferies Healthcare Conference(Yahoo Finance)
2023-05-30 20:04
Enlivex Selected for an Elevator Pitch Presentation and two additional Poster Presentations at the 2023 Annual Meeting of the International Society for Cell & Gene Therapy(Yahoo Finance)
2023-05-07 20:00
Enlivex Announces Issuance of European Patent Covering the Use of Allocetra to Prevent Cytokine Release Syndrome (CRS) Resulting from CAR T-Cell Therapy(Yahoo Finance)
2023-04-19 22:18
We Think Enlivex Therapeutics (NASDAQ:ENLV) Needs To Drive Business Growth Carefully(Yahoo Finance)
2023-04-18 20:00
Enlivex Receives Notice of Allowance for U.S. Patent Application Covering the Use of Allocetra in Patients Receiving CAR T-Cell Therapy(Yahoo Finance)
2023-04-16 20:00
Enlivex Appoints Andrew Singer to its Board of Directors(Yahoo Finance)
2023-04-13 21:40
Analysts At H.C. Wainwright & Co. Set 12-Month Target Of $15 Per Share For ENLV Thanks To High Profile Collaboration Agreement, Multiple Ongoing Clinical Trials(Yahoo Finance)
2023-04-11 22:45
Enlivex, Beigene Collaborate To Test A New Combination Treatment To Fight Advanced-Stage Solid Tumors(Yahoo Finance)
2023-04-09 15:07
BeiGene, Ltd. (BGNE) Surges 12.5%: Is This an Indication of Further Gains?(Yahoo Finance)
2023-04-03 20:00
Enlivex Announces Tislelizumab Clinical Collaboration, Full Year 2022 Financial Results, and Provides Business Updates(Yahoo Finance)
2023-04-02 20:00
Enlivex Announces Clinical Collaboration to Evaluate Combinations of Allocetra and PD-1 Inhibitor Tislelizumab for Patients with Solid Tumors(Yahoo Finance)

Page 1 of 4

previousnext